An ambulatory blood pressure monitoring study of TLANDO
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Adverse reactions
- 22 Nov 2018 New trial record
- 07 Nov 2018 According to the Lipocine media release, results from the trial are expected in the first quarter of 2019. This study is being conducted to address the blood pressure related concern cited in the FDA's Complete Response Letter issued May 2018, in response to Testosterone-undecanoate NDA.
- 01 Nov 2018 Status changed from recruiting to active, no longer recruiting, as reported in the Lipocine media release.